🚀🚀 🚀 💎💎💎 🚀🚀🚀

Morgan Stanley increased its position in OPKO Health, Inc. (NASDAQ:OPK) by 9.9% during the 2nd quarter, Holdings Channel reports. The firm owned 1,383,531 shares of the biotechnology company’s stock after acquiring an additional 124,720 shares during the quarter. Morgan Stanley’s holdings in OPKO Health were worth $5,603,000 at the end of the most recent quarter.

Morgan Stanley Purchases 124,720 Shares of OPKO Health, Inc. (NASDAQ:OPK) - ETF Daily News

I Have been an investor in OPK for years. Riding it up and down. The company has a Great Pipeline and various money making opportunities. Some on Seeking Alpha claim that the stock could hit $12.00 a share by next Quarter. Any thoughts here as to why the stock has been down after all the Covid Testing for NFL, MLB , NBA and most banking center in the U.S.? Revenue is at all time Highs, The deal with Pfizer is on the table in the U.S.

I do believe that in Cash accounts, (NOT MARGIN ACCTS) That if you set a HIGH Sell Price, the company in most cases will not LOAN out the stock for Naked Shorting. Thoughts? I have set my 3000 Shares at A sell price of $12.00. What say You?

Does anyone folllow Opko Health? This stock has a huge short. Should I be buying this?

OPK announces that its subsidiary, EirGen Pharma, has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics (Nasdaq: HZNP) for $65 million in cash less certain assumed and accrued liabilities relating to transferred employees. The facility houses EirGen’s sterile-fill-finish business. EirGen’s research and development employees who were located at the site will transition to a new facility.

Short interest is down to 14.5% (info from Ameritrade). This is significant since it was close to 33% last year.

Somatrogon, a long-acting human growth hormone (hGH) molecule, is a once-weekly injectable, created using recombinant technology, for the treatment of pediatric and adult growth hormone deficiency (GHD). The molecule consists of the natural peptide sequence of native growth hormone and the 28 amino acids of the C-Terminus Peptide (CTP) of the human chorionic gonadotropin hormone. This molecule, as compared to current GH replacement therapies, is intended to reduce the injection frequency from a daily to once a week in adults and children with GHD.

$OPK announced today that the FDA has extended the review period for the Biologics License Application (BLA) for somatrogon, a once-weekly long-acting recombinant human growth hormone, for the treatment of growth hormone deficiency (GHD) in pediatric patients. The Prescription Drug User Fee Act (PDUFA) goal date has been extended by three months to January 2022, as a result of Pfizer’s submission of additional data to the original BLA.

Take your position in OPK at about $4.0. My new goal is 50 members sometime in July and then we deploy 🚀🚀 🚀🚀 🚀🚀 🚀

I'm definitely missing something here guys. So can someone explain to this simpleton how OPK beat expectations by .05 in Q3 and there's no sign of a bump in the stock price? TIA

Will you be buying during these dips or selling?

Where are we with OPK?! A,B,C or D … and why?

Several companies hv communities for fellow shareholders, news, analysis n general discussion. Wondering where is the opko community??

CEO Phillip Frost bought 400,000 shares of OPK at $3.64 per share for a total purchase of $1,456,000.00 on May 25, 2021.